EP2432882B1 - TREATMENT of TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES by INHIBITION of NATURAL ANTISENSE TRANSCRIPT to TFE3